Michael Lawson, MD
Internal Medicine · Kearney, NENPI 1205819455
Payments from drug & device makers
Across 21 payments — averaging $17.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$199
- Pfizer$55
- Abbott$32
- Astellas Pharma US Inc$26
- Sanofi$21
- Novo Nordisk$14
- plus $11 from 1 others
What the payments were for
- Food & beverage$359100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 12 | $199 |
| Pfizer | 3 | $55 |
| Abbott | 2 | $32 |
| Astellas Pharma US Inc | 1 | $26 |
| Sanofi | 1 | $21 |
| Novo Nordisk | 1 | $14 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $11 |
How this compares
$359 in reported general payments places this provider in the 65th percentile of 570 internal medicine providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 99 | $122,162 |
| EliquisApixaban | 99 | $61,998 |
| XareltoRivaroxaban | 46 | $40,718 |
| TrulicityDulaglutide | 32 | $35,758 |
| MounjaroTirzepatide | 24 | $25,444 |
| Tresiba Flextouch U-100Insulin Degludec | 48 | $24,277 |
| Xultophy 100-3.6Insulin Degludec/Liraglutide | 16 | $20,822 |
| MyrbetriqMirabegron | 54 | $17,737 |
| FarxigaDapagliflozin Propanediol | 30 | $16,631 |
| JardianceEmpagliflozin | 15 | $15,990 |
| Tresiba Flextouch U-200Insulin Degludec | 25 | $15,694 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 24 | $12,862 |
| Omnipod Dash Pods (Gen 4)Insulin Pump Cart,cont Inf,bt | 18 | $12,160 |
| LunestaEszopiclone | 11 | $11,238 |
| JanuviaSitagliptin Phosphate | 16 | $11,068 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Xultophy 100-3.6 | $14 | $142,984115 claims |
| PfizerEliquis | $55 | $61,99899 claims |
| Astellas Pharma US IncMyrbetriq | $26 | $17,73754 claims |
| AbbVieSynthroid | $199 | $4,13749 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 570 internal medicine providers in Nebraska.
Other internal medicine in Kearney
- Bhavish AubeelauckKearney$4K
- Scott RasmussenLincoln$38.1M
- Charles HarperNorfolk$31.1M
- Robert SchwabBoys Town$9.2M
- Michael DunnOmaha$7.9M
- Alexander RyanLincoln$2.2M
- Joel MichalskiOmaha$1.6M
- Ariana BauerOmaha$1.5M
- David CrockettOmaha$821K
- Timothy HuyckPapillion$702K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.